How India Exports Atazanavir to the World

Atazanavir, an antiretroviral medication used in the treatment of HIV, has a significant presence in the U.S. market. According to the FDA's Orange Book, there are multiple approved Abbreviated New Drug Applications (ANDAs) for Atazanavir, indicating a competitive generic landscape. Notably, in June 2025, the FDA approved an ANDA for Atazanavir Sulfate Capsules, 300 mg, submitted by a leading generic pharmaceutical company, further expanding the availability of this medication. As of March 2026, there are no active FDA import alerts related to Atazanavir, suggesting compliance with U.S. regulatory standards by exporters. Given that 17 Indian exporters are actively involved in the Atazanavir market, adherence to FDA regulations is crucial for maintaining market access.

In the European Union, Atazanavir is subject to marketing authorization by the European Medicines Agency (EMA). The EMA granted marketing authorization for Atazanavir in December 2004, and it has since been included in the centralized procedure, allowing for uniform approval across EU member states. The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) continues to recognize EMA approvals post-Brexit, ensuring continuity in the availability of Atazanavir. Compliance with EU Good Manufacturing Practice (GMP) requirements is mandatory for manufacturers, including those in India, to export Atazanavir to these markets.

Atazanavir is listed in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in global health. It was first included in the 18th edition, published in April 2013. The WHO Prequalification Programme has also prequalified several generic versions of Atazanavir, facilitating their procurement by UN agencies and other international organizations. Additionally, Atazanavir is included in major pharmacopoeias such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality specifications across different regions.

In India, Atazanavir is classified under Schedule H of the Drugs and Cosmetics Act, requiring a prescription for its dispensation. The National Pharmaceutical Pricing Authority (NPPA) has set a ceiling price for Atazanavir, with the latest revision in August 2025, to ensure affordability. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) for certain pharmaceutical products; however, Atazanavir is currently exempt from this requirement, streamlining the export process for Indian manufacturers.

The primary patents for Atazanavir have expired, leading to increased generic competition. This has resulted in a decrease in prices and expanded access to the medication globally. Indian pharmaceutical companies have capitalized on this opportunity, with Mylan Laboratories Limited capturing a 62.9% share of Atazanavir exports from India, amounting to $44.8 million USD.

In May 2025, the Indian Ministry of Health and Family Welfare implemented new guidelines to expedite the approval process for generic antiretroviral drugs, including Atazanavir, aiming to enhance the availability of affordable HIV treatments. Subsequently, in September 2025, the NPPA revised the ceiling price of Atazanavir, reducing it by 10% to reflect the decreasing cost of production and to make the drug more accessible to patients.

Furthermore, in November 2025, the WHO Prequalification Programme added two new Indian manufacturers of Atazanavir to its list, recognizing their compliance with international quality standards. This development is expected to bolster the global supply chain and support international procurement initiatives. Additionally, in January 2026, the World Trade Organization (WTO) reported a 5% increase in the global demand for antiretroviral drugs, including Atazanavir, highlighting the ongoing need for effective HIV treatments worldwide.

The production of atazanavir relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs). India, while a major producer of APIs, depends heavily on China for KSMs. According to the U.S. Pharmacopeia, 41% of KSMs used in U.S.-approved APIs are solely sourced from China, and 16% from India, indicating a significant reliance on these two countries. This dependency poses a risk, as any disruption in China's supply chain can directly affect India's API production capabilities.

In recent years, environmental regulations in China have led to the shutdown of numerous chemical plants. For instance, over the past year, nearly 145 API manufacturers in China ceased operations due to non-compliance with pollution norms, causing supply disruptions and cost escalations. Such events underscore the vulnerability of India's pharmaceutical industry to external supply chain disturbances.

The export data reveals a high supplier concentration, with the top five exporters accounting for 99.2% of atazanavir exports. Notably, MYLAN LABORATORIES LIMITED alone holds a 62.9% share, amounting to $44.8 million USD. This concentration indicates a significant single-source risk; any operational issues within these key companies could disrupt the global supply of atazanavir.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic manufacturing of APIs and reduce reliance on imports. In October 2024, two greenfield plants were inaugurated under this scheme to produce critical molecules like Penicillin G and 6-APA, essential for antibiotics. While this initiative is a positive step, its impact on atazanavir's supply chain remains to be seen.

Global shipping routes, including the Red Sea and the Strait of Hormuz, are susceptible to geopolitical tensions, which can lead to delays and increased transportation costs. Additionally, escalating U.S.-China trade tensions have prompted regulatory actions, such as the BIOSECURE Act and the FDA's PreCheck pilot program, aiming to reduce dependency on foreign APIs. These measures could disrupt existing supply chains and necessitate adjustments in sourcing strategies.

Furthermore, regulatory scrutiny can impact API availability. For example, in 2022, a major Indian facility producing acyclovir intermediates faced regulatory action, leading to global supply shortages and price hikes. Such incidents highlight the potential for regulatory events to cause significant supply chain disruptions.

• Diversify API and KSM Sources: Encourage the development of alternative suppliers for APIs and KSMs to reduce dependency on a single country or company.

• Strengthen Domestic Manufacturing: Expand initiatives like the PLI scheme to include a broader range of APIs and KSMs, ensuring a more resilient domestic supply chain.

• Enhance Regulatory Compliance: Implement stringent quality control measures to prevent regulatory actions that could disrupt production and supply.

• Develop Strategic Reserves: Establish stockpiles of critical APIs and KSMs to buffer against short-term supply disruptions.

• Monitor Geopolitical Developments: Stay informed about international trade policies and geopolitical events that could impact supply chains, allowing for proactive adjustments.

RISK_LEVEL: MEDIUM